Sunshine Biopharma reported earnings of -$ 5.20 per SBFMW share on Nov 13, 2026, beating analysts' expectations by
| Report Date | Nov 13, 2026 |
|---|---|
| Forecasted EPS | -$ 3.40 |
| Earnings Per Share (Surprise) | -$ 5.20 (-$ 1.80) |
| Last Year's EPS | -$ 5.07 |
| EPS YoY Change |
Out of the last 22 earnings reporting periods, Sunshine Biopharma beat analysts’ expectations 6 times and fell short of expectations 9 time(s). Sunshine Biopharma reported earnings per share of -$ 5.20 in the last report falling to reach an estimated EPS of -$ 3.40 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 3.40 | -$ 5.20 | -$ 3.00 | |
| Nov 12, 2026 | -$ 3.40 | -$ 5.20 | -$ 1.90 | |
| Aug 13, 2026 | -$ 1.20 | -$ 1.15 | -$ 3.90 | |
| May 13, 2026 | -$ 2.50 | -$ 2.50 | -$ 4.40 | |
| Apr 3, 2026 | -$ 2.70 | -$ 3.00 | -$ 10.10 | |
| Nov 13, 2025 | -$ 1.30 | -$ 1.90 | -$ 9.40 | |
| Aug 12, 2025 | -$ 1.10 | -$ 3.90 | -$ 0.99 | |
| May 15, 2025 | -$ 1.10 | -$ 4.40 | -$ 40.00 | |
| Apr 1, 2025 | $ 0.10 | -$ 10.10 | -$ 1.00 | |
| Nov 6, 2024 | -$ 5,350.00 | -$ 9.40 | -$ 0.80 | |
| Aug 19, 2024 | -$ 0.06 | -$ 0.99 | -$ 40.00 | |
| May 20, 2024 | -$ 160.00 | -$ 40.00 | -$ 0.08 | |
| Mar 28, 2024 | -$ 0.60 | -$ 1.00 | -$ 0.08 | |
| Nov 13, 2023 | -$ 1.20 | -$ 0.80 | -$ 3.40 | |
| Aug 10, 2023 | -$ 160.00 | -$ 40.00 | $ 0.00 | |
| May 10, 2023 | -$ 160.00 | -$ 0.08 | $ 0.0003000 | |
| Nov 7, 2022 | - | -$ 0.08 | $ 0.00 | |
| Aug 3, 2022 | - | -$ 3.40 | $ 0.00 | |
| May 6, 2022 | - | $ 0.00 | - | - |
| Mar 21, 2022 | - | $ 0.0003000 | - | - |
Sunshine Biopharma’s stock was trading at on Nov 12, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Aug 13, 2026 | -$ 1.15 | $ 0.0429 | ||
| May 13, 2026 | -$ 2.50 | $ 0.0851 | $ 0.0851 | |
| Apr 3, 2026 | -$ 3.00 | $ 0.0851 | $ 0.0851 | |
| Nov 13, 2025 | -$ 1.90 | $ 0.2453 | $ 0.21 | |
| Aug 12, 2025 | -$ 3.90 | $ 0.2143 | $ 0.1621 | |
| May 15, 2025 | -$ 4.40 | $ 0.1986 | $ 0.23 | |
| Apr 1, 2025 | -$ 10.10 | $ 0.2016 | $ 0.28 | |
| Nov 6, 2024 | -$ 9.40 | $ 0.1363 | $ 0.1304 | |
| Aug 19, 2024 | -$ 0.99 | $ 0.1199 | $ 0.10 | |
| May 20, 2024 | -$ 40.00 | $ 0.0911 | $ 0.11 | |
| Mar 28, 2024 | -$ 1.00 | $ 0.06 | $ 0.0724 | |
| Nov 13, 2023 | -$ 0.80 | $ 0.17 | $ 0.1701 | |
| Aug 10, 2023 | -$ 40.00 | $ 0.3499 | $ 0.3498 | |
| May 10, 2023 | -$ 0.08 | $ 0.4899 | $ 0.61 | |
| Nov 7, 2022 | -$ 0.08 | $ 0.3604 | $ 0.4531 | |
| Aug 3, 2022 | -$ 3.40 | $ 0.75 | $ 0.75 | |
| May 6, 2022 | $ 0.00 | $ 1.96 | $ 1.41 | |
| Mar 21, 2022 | $ 0.0003000 | $ 1.06 | $ 0.98 |
Sunshine Biopharma released its most recent earnings reports in November 2026, November 2026, August 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Sunshine Biopharma missed analysts’ expectations during the last earnings period by
